| OCUGEN INC. DL-,001 |
| USA |
| Gesundheit |
| US67577C1053 / A2PSZH |
| 2H51 (Frankfurt) / OCGN (NASDAQ) |
| FRA:2H51, ETR:2H51, 2H51:GR, NASDAQ:OCGN |
| - |
| https://ocugen.com/ |
|
Ocugen Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for blindness diseases and other serious ocular conditions. Its current programs center on a modifier gene therapy platform designed to address in..
>Volltext.. |
| 245.51 Mio. EUR |
| 234.96 Mio. EUR |
| 4.08 Mio. EUR |
| -59.77 Mio. EUR |
| -72.79 Mio. EUR |
| -0.23 EUR |
| 78.29 Mio. EUR |
| 89.02 Mio. EUR |
| -54.16 Mio. EUR |
| 0.75 |
| -0.63% |
| -48.2% |
| - |
| - |
| - |
| OCUGEN |
| 20.10.26 |
|
||||
|
||||
|
||||
|